September 29, 2014 the parent counsel for bile acid deficiency disorders was received by the FDA, Division of Gastroenterology & Inborn Error Products, to relate their children’s case histories and treatment. After listening to Matthew’s case history, the FDA, specifically Dr. Andrew Mulberg, Deputy Division Director, took express note of the facts that the DHA-EE had stopped Matthew’s steatorrhea and improved his liver function, and that the cholic acid had further improved his liver function.
Matthew’s Medical Summary for FDA
